Anatomy and Cell Biology

Korean Association of Anatomists (대한해부학회)
권호 표지
DOI QR코드

DOI QR Code

Blood-retina barrier dysfunction in experimental autoimmune uveitis: the pathogenesis and therapeutic targets

  • Jeongtae Kim (Department of Anatomy, Kosin University College of Medicine) ;
  • Jiyoon Chun (Department of Veterinary Anatomy, College of Veterinary Medicine and Veterinary Medical Research Institute, Jeju National University) ;
  • Meejung Ahn (Department of Animal Science, College of Life Science, Sangji University) ;
  • Kyungsook Jung (Functional Biomaterials Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Changjong Moon (Department of Veterinary Anatomy, College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University) ;
  • Taekyun Shin (Department of Veterinary Anatomy, College of Veterinary Medicine and Veterinary Medical Research Institute, Jeju National University)
  • Received : 2021.11.12
  • Accepted : 2022.01.06
  • Published : 2022.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Experimental autoimmune uveitis (EAU), an animal model of human uveitis, is characterized by infiltration of autoimmune T cells in the uvea as well as in the retina of susceptible animals. EAU is induced by the immunization of uveitogenic antigens, including either retinal soluble-antigen or interphotoreceptor retinoid-binding proteins, in Lewis rats. The pathogenesis of EAU in rats involves the proliferation of autoimmune T cells in peripheral lymphoid tissues and breakdown of the blood-retinal barrier, primarily in the uvea and retina, finally inducing visual dysfunction. In this review, we describe recent EAU studies to facilitate the design of a therapeutic strategy through the interruption of uveitogenic factors during the course of EAU, which will be helpful for controlling human uveitis.

Keywords

Acknowledgement

This research was supported by the National Research Foundation of Korea (Grant number: NRF- 2019R1A2C1087753) and a grant from Kosin University College of Medicine (2021).

References

  1. Jabs DA. Immunosuppression for the uveitides. Ophthalmology 2018;125:193-202. 
  2. Chmielewski NT, Brooks DE, Smith PJ, Hendrix DV, Whittaker C, Gelatt KN. Visual outcome and ocular survival following iris prolapse in the horse: a review of 32 cases. Equine Vet J 1997;29:31-9. 
  3. de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-70. 
  4. Mattapallil MJ, Silver PB, Mattapallil JJ, Horai R, Karabekian Z, McDowell JH, Chan CC, James EA, Kwok WW, Sen HN, Nussenblatt RB, David CS, Caspi RR. Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol 2011;187:1977-85. 
  5. Wildner G, Diedrichs-Mohring M, Thurau SR. Rat models of autoimmune uveitis. Ophthalmic Res 2008;40:141-4. 
  6. Caspi RR. Understanding autoimmunity in the eye: from animal models to novel therapies. Discov Med 2014;17:155-62. 
  7. Klaska IP, Forrester JV. Mouse models of autoimmune uveitis. Curr Pharm Des 2015;21:2453-67. 
  8. Diedrichs-Mohring M, Kaufmann U, Wildner G. The immunopathogenesis of chronic and relapsing autoimmune uveitis - lessons from experimental rat models. Prog Retin Eye Res 2018;65:107-26. 
  9. Kyger M, Worley A, Huan J, McDowell H, Smith WC, Burrows GG, Mattapallil MJ, Caspi RR, Adamus G. Effective arrestin-specific immunotherapy of experimental autoimmune uveitis with RTL: a prospect for treatment of human uveitis. Transl Vis Sci Technol 2013;2:1. 
  10. Agarwal RK, Silver PB, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Biol 2012;900:443-69. 
  11. Kang J, Ahn M, Moon C, Min DS, Matsumoto Y, Shin T. Phospholipase D1 is up-regulated in the retina of Lewis rats with experimental autoimmune uveoretinitis. Immunol Invest 2005;34:27-36. 
  12. Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol 2003;Chapter 15:Unit 15.6. 
  13. Egwuagu CE, Mahdi RM, Nussenblatt RB, Gery I, Caspi RR. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens. J Immunol 1993;151:1627-36. 
  14. Diedrichs-Mohring M, Hoffmann C, Wildner G. Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. Int Immunol 2008;20:365-74. 
  15. Yin X, Liu B, Wei H, Wu S, Guo L, Xu F, Liu T, Bi H, Guo D. Activation of the Notch signaling pathway disturbs the CD4+/CD8+, Th17/Treg balance in rats with experimental autoimmune uveitis. Inflamm Res 2019;68:761-74. 
  16. Jia X, Hu M, Wang C, Wang C, Zhang F, Han Q, Zhao R, Huang Q, Xu H, Yuan H, Ren H. Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis. Mol Vis 2011;17:1493-507. 
  17. Kim G, Kohyama K, Tanuma N, Arimito H, Matsumoto Y. Persistent expression of experimental autoimmune encephalomyelitis (EAE)-specific Vbeta8.2 TCR spectratype in the central nervous system of rats with chronic relapsing EAE. J Immunol 1998;161:6993-8. 
  18. Buenafe AC, Offner H, Machnicki M, Elerding H, Adlard K, Jacobs R, Vandenbark AA, Adamus G. EAE TCR motifs and antigen recognition in myelin basic protein-induced anterior uveitis in Lewis rats. J Immunol 1998;161:2052-9. 
  19. Chan CC, Caspi R, Mochizuki M, Diamantstein T, Gery I, Nussenblatt RB. Cyclosporine and dexamethasone inhibit T-lymphocyte MHC class II antigens and IL-2 receptor expression in experimental autoimmune uveitis. Immunol Invest 1987;16:319-31. 
  20. Lobanoff MC, Kozhich AT, Mullet DI, Gerber N, Gery I, Chan CC, Whitcup SM. Effect of gallium nitrate on experimental autoimmune uveitis. Exp Eye Res 1997;65:797-801. 
  21. Toriyama S. Effects of leukotriene B(4) receptor antagonist on experimental autoimmune uveoretinitis in rats. Jpn J Ophthalmol 2000;44:695. 
  22. Liang W, Karabekian Z, Mattapallil M, Xu Q, Viley AM, Caspi R, Scott DW. B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis. Clin Immunol 2006;118:35-41. Erratum in: Clin Immunol 2006;120:357. 
  23. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y, Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006;82:657-63. 
  24. Osada M, Sakai T, Kuroyanagi K, Kohno H, Tsuneoka H. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate. Mol Vis 2014;20:1518-26. 
  25. Kim J, Ahn M, Choi Y, Chun J, Jung K, Tanaka A, Matsuda H, Shin T. Osteopontin is a biomarker for early autoimmune uveoretinitis. Neural Regen Res 2022;17:1604-8. 
  26. Dick AD, Cheng YF, Liversidge J, Forrester JV. Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens. Eye (Lond) 1994;8(Pt 1):52-9. 
  27. Greenwood J, Howes R, Lightman S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab Invest 1994;70:39-52. 
  28. Rao NA, Kimoto T, Zamir E, Giri R, Wang R, Ito S, Pararajasegaram G, Read RW, Wu GS. Pathogenic role of retinal microglia in experimental uveoretinitis. Invest Ophthalmol Vis Sci 2003;44:22-31. 
  29. Chiba C. The retinal pigment epithelium: an important player of retinal disorders and regeneration. Exp Eye Res 2014;123:107-14. 
  30. Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, Tobe T, Campochiaro PA, Vinores SA. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 1997;49:268-80. 
  31. Prendergast RA, Iliff CE, Coskuncan NM, Caspi RR, Sartani G, Tarrant TK, Lutty GA, McLeod DS. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 1998;39:754-62. 
  32. Tyler NK, Burns MS. Comparison of lectin reactivity in the vessel beds of the rat eye. Curr Eye Res 1991;10:801-10. 
  33. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-37. 
  34. Pavan B, Dalpiaz A. Retinal pigment epithelial cells as a therapeutic tool and target against retinopathies. Drug Discov Today 2018;23:1672-9. 
  35. Lee H, Hwang-Bo H, Ji SY, Kim MY, Kim SY, Park C, Hong SH, Kim GY, Song KS, Hyun JW, Choi YH. Diesel particulate matter2.5 promotes epithelial-mesenchymal transition of human retinal pigment epithelial cells via generation of reactive oxygen species. Environ Pollut 2020;262:114301. 
  36. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005;85:597-607. 
  37. Zhang R, Yang PZ, Wu CY, Jin HL, Li B, Huang XK, Zhou HY, Gao Y, Zhu LX, Kijlstra A. Role of T-cell receptor V beta 8.3 peptide vaccine in the prevention of experimental autoimmune uveoretinitis. Chin Med J (Engl) 2006;119:740-8. 
  38. Wu W, Zhang Z, Xiong T, Zhao W, Jiang R, Chen H, Li X. Calcium ion coordinated dexamethasone supramolecular hydrogel as therapeutic alternative for control of non-infectious uveitis. Acta Biomater 2017;61:157-68. 
  39. Robertson M, Liversidge J, Forrester JV, Dick AD. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003;44:3034-41. 
  40. Kwak HJ, Yang YS, Pae HO, Kim YM, Chung HT. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response. Mol Cells 2001;12:178-84. 
  41. Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011;52:1516-21. 
  42. Johnsen-Soriano S, Sancho-Tello M, Arnal E, Diaz-Llopis M, Navea A, Miranda M, Bosch-Morell F, Romero FJ. Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model. Ocul Immunol Inflamm 2010;18:208-15. 
  43. Crupi R, Impellizzeri D, Gugliandolo E, Cordaro M, Siracusa R, Britti D, Cuzzocrea S, Di Paola R. Effect of Tempol, a membrane-permeable free radical scavenger, on in vitro model of eye inflammation on rabbit corneal cells. J Ocul Pharmacol Ther 2019;35:571-7. 
  44. Rajendram R, Saraswathy S, Rao NA. Photoreceptor mitochondrial oxidative stress in early experimental autoimmune uveoretinitis. Br J Ophthalmol 2007;91:531-7. 
  45. Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Behcet's disease duration, activity and severity. Eur J Intern Med 2008;19:541-7. 
  46. Augustin AJ, Loeffler KU, Sekundo W, Grus FH, Lutz J. Effects of systemically applied allopurinol and prednisolone on experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol 1999;237:508-12. 
  47. Sasaki H, Lin LR, Yokoyama T, Sevilla MD, Reddy VN, Giblin FJ. TEMPOL protects against lens DNA strand breaks and cataract in the x-rayed rabbit. Invest Ophthalmol Vis Sci 1998;39:544-52. 
  48. Zamir E, Zhang R, Samuni A, Kogan M, Pe'er J. Nitroxide stable radical suppresses autoimmune uveitis in rats. Free Radic Biol Med 1999;27:7-15. 
  49. Yadav UC, Shoeb M, Srivastava SK, Ramana KV. Amelioration of experimental autoimmune uveoretinitis by aldose reductase inhibition in Lewis rats. Invest Ophthalmol Vis Sci 2011;52:8033-41. 
  50. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, Martinello M, Cattalini A, Bergami A, Furlan R, Comi G, Constantin G, Martino G. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005;436:266-71. 
  51. Uchio E, Kijima M, Tanaka S, Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci 1994;35:2626-31. 
  52. Kitaichi N, Matsuda A, Kotake S, Namba K, Tagawa Y, Sasamoto Y, Ogasawara K, Iwabuchi K, Onoe K, Matsuda H, Nishihira J. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies. Curr Eye Res 2000;20:109-14. 
  53. Wallace GR, Whiston RA, Stanford MR, Wells GM, Gearing AJ, Clements JM. The matrix metalloproteinase inhibitor BB1101 prevents experimental autoimmune uveoretinitis (EAU). Clin Exp Immunol 1999;118:364-70.